American College of Physicians [46] –Screening, monitoring, and treatment of stage 1-3 CKD National Kidney Foundation–Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) – Evaluation, Classification, and Stratification [4, 5, 49, 104] ; CKD mineral and bone disorder [83] ; lipid managem...
Uremic manifestations in patients with CKD stage 5 are believed to be primarily secondary to an accumulation of multiple toxins, the full spectrum and identity of which is generally not known. Metabolic acidosis in stage 5 may manifest as protein-energy malnutrition, loss of lean body mass, and...
The present systematic review and meta-analysis explores the benefits of 5 treatment modalities for calcific uremic arteriolopathy or calciphylaxis in patients with CKD, including end-stage renal disease. We focused on 2 clinical outcomes: wound healing and mortality. At time of diagnosis, most pat...
Records Database: Rates of Diagnosis and Antihyperglycemic Medication Dose Adjustment Juli . Meyers, MA1 Sean D. Candrilli, PhD2 Objective: To assess rates of diagnosis and antihyperglycemic dose adjustment in patients with Birgit Kovacs, MD3 moderate to end-stage renal impairment (RI) and type ...
* The presence and extent of vascular calcifications are strong predictors of cardiovascular and all-cause mortality, as demonstrated in this study of 110 patients with stable end-stage renal disease receiving hemodialysis.1 The presence of calcifications was detected by ultrasound, and results were ...
Vadadustat from Akebia (AKB-6548), an HIF-PH inhibitor, is currently in the phase 3 stage of development for the treatment of anemia secondary to CKD. In a phase 1a single-dose study in 8 healthy men (6 receiving vadadustat and 2 receiving placebo), vadadustat was observed to have ...
Low blood pressure was not observed as a significant risk factor for progression to end-stage kidney disease [18]. Other risk factors for new-onset chronic kidney disease AF was an independent risk factor for new-onset proteinuria in non-CKD participants in men. In our previous report, AF ...
Patients with thromboembolic events had slightly higher median hsCRP, lower median ferritin, lower median TSAT, and higher median transferrin compared with those without thromboembolic events, especially at the late stage (weeks 36–52) of the treatment period. Fig. 2 Medians ± interquartile...
Ifosfamide is a nitrogen mustard alkylating agent used as both a first-line and a salvage chemotherapeutic agent in the treatment of testicular germ cell tumors, various sarcomas, carcinomas, and some lymphomas. A well-known complication of ifosfamide therapy is transient acute kidney injury. ...
***中国专家共识历经半年的准备第25页,共36页,5月,星期六,2024年,5月中国专家共识的制订充分参考国内外指南第26页,共36页,5月,星期六,2024年,5月共识制订中口服降糖药评价原则如缺乏用药经验,则依据从严原则第27页,共36页,5月,星期六,2024年,5月注:深蓝箭头表示无需减量浅色箭头表示减量虚线箭头表示用药经...